Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The molecular mechanisms underlying epidermal growth factor (EGF) receptor tyrosine kinase down-regulation in response to growth factor binding are coming into focus and involve cbl-mediated receptor ubiquitination followed by lysosomal degradation. However, mechanisms underlying the ligand-stimulated degradation of the related receptor tyrosine kinases of the ErbB family do not involve cbl and remain unexplored. Previous studies have demonstrated that the E3 ubiquitin ligase Nrdp1 contributes to the maintenance of steady-state ErbB3 levels by mediating its growth factor-independent degradation. Here we demonstrate that treatment of cells with the ErbB3 ligand neuregulin-1 (NRG1) stabilizes the deubiquitinating enzyme USP8, which in turn stabilizes Nrdp1. The catalytic activity of USP8 is required for NRG1-induced Nrdp1 stabilization. We provide evidence that Akt-mediated phosphorylation of USP8 threonine residue T907 contributes to USP8 stability. Finally, we demonstrate that Nrdp1 or USP8 knockdown suppresses NRG1-induced ErbB3 ubiquitination and degradation in MCF7 breast cancer cells. We conclude that an NRG1-induced protein stability cascade involving USP8 and Nrdp1 mediates the down-regulation of ErbB3. Our observations raise the possibility that the ligand-induced augmentation of pathways involved in the maintenance of basal levels of receptor tyrosine kinases can contribute to ligand-stimulated down-regulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the rhodanese-like domain (Rhod) of USP8 is known to bind the E3 ligase, Nrdp1, and in so doing indirectly influences the degradation of Erb-B3 (33,36,37).”
From Regulation of Epidermal Growth Factor Receptor Ubiquitination and Trafficking by the USP8·STAM Complex (2010) · cites this paper as [36]
In the citing paper
“Ubiquitin-mediated protein degradation has been shown to regulate ErbB3 (Cao, 2007), but this process is on the order of several hours, which is too slow to account for the observed dynamics of ErbB3 phosphorylation.”
From Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data (2009) · cites this paper as Cao, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“For example, amplification of the erbB2 gene is observed in 25 to 30% of breast cancer patients, and overexpression of the product correlates with an earlier relapse and poor prognosis (46, 47).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Receptor downregulation and multivesicular-body sorting
Katzmann, D. J., Odorizzi, G., & Emr, S. D. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm973 · Cited by 1,201
Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80231-2 · Cited by 1,001
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation
Haglund, K., Sigismund, S., Polo, S., Szymkiewicz, I., Di Fiore, P. P., & Dikic, I. (2003) · Nature Cell Biology · doi:10.1038/ncb983 · Cited by 715
Alroy, I., & Yarden, Y. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00412-2 · Cited by 714
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · cited 1×
“Since ErbB3 lacks intrinsic tyrosine kinase activity (16) and no diffusible ligand that binds to ErbB2 has been described, these two receptors must necessarily collaborate in propagating signals in response to growth factors such as the ErbB3 ligand neuregulin-1 (NRG1) ( 9, 48).”
BackgroundSelf-citationCoexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., & Carraway, K. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36676-0 · Cited by 643
Self-citation
Research works printed but not linked: 1
- 42. Riese, D. J., II, and D. F. Stern. 1998. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41-48. · DOI · Paper page
Cited by
Items 101–125 of 125
Ubiquitin Specific Peptidase 8
Berruti, G., & Martegani, E. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382219-2.00466-x · Cited by 3
Zuo, W., Luo, S., Qin, H., Wong, K. H., Siu, S. W. I., Tashima, A. K., Assaraf, Y. G., & Kwok, H. F. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02856-6 · Cited by 2
Wang, S., Li, K., Gao, H., Liu, Z., Shi, S., Tan, Q., & Wang, Z. (2021) · Czech Journal of Animal Science · doi:10.17221/105/2020-cjas · Cited by 2
Sorkin, A. D. (2009) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-540-87941-1_11 · Cited by 1
Targeting Deubiquitinating Enzymes
Priolo, C., Oldridge, D. A., Renatus, M., & Loda, M. F. (2009) · Springer eBooks · doi:10.1007/978-0-387-69147-3_8 · Cited by 1
ENGINEERED MULTIVALENCY FOR ENHANCED AFFIBODY-BASED HER3 CANCER THERAPY
Schardt, J. S. (2018) · University Libraries (University of Maryland) · doi:10.13016/m2q23r36b · Cited by 1
Growth Factors: Protein Processing, Endocytosis, and Intracellular Sorting
Duex, J. E., & Sorkin, A. D. (2010) · Wiley eBooks · doi:10.1002/9780470054581.eib508
Molecular Mechanism of Ubiquitin-Dependent Traffic
Maspero, E., Wollscheid, H.-P., & Polo, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6528-7_10
THERAPEUTIC POTENTIAL OF EGFR DERIVED PEPTIDES IN BREAST CANCER
Su, H. (2013) · UA Campus Repository (The University of Arizona)
Role of ErbB2 and ErbB4 in Cancer Growth, Prognosis and as Targets for Immunotherapy
Hollmén, M. (2010) · UTUPub (University of Turku) · Cited by 1
Ho, Y., Starr, T. K., LaRue, R. S., & Largaespada, D. A. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0176-7
Mechanisms Involved in Endocytosis of ErbB Proteins
Breen, K. (2008) · NVA (Nasjonalt vitenarkiv)
Molecular mechanisms controlling endocytic downregulation of EGFR and ErbB3
Sak, M. M. (2013) · NVA (Nasjonalt vitenarkiv)
Unveiling Ubiquitination as a New Regulatory Mechanism of the ESCRT-III Protein CHMP1B
Crespo-Yàñez, X. (2017) · theses.fr (ABES) · doi:10.70675/483d8170z2e15z4b2fz8792z4f1b71d55f1a
Hayes, D. (2019) · UTAS Research Repository · doi:10.25959/100.00031712
Ubiquitin-Proteasome System Modulates Platelet Function
Gupta, N. (2014) · EngagedScholarship @ Cleveland State University (Cleveland State University) · doi:10.13140/rg.2.2.17121.25449 · Cited by 2
Richman, J. M. (2008) · Digital Repository Service (Northeastern University) · doi:10.17760/d10016788 · Cited by 1
Chen, L., Siddiqui, S., Bose, S., Mooso, B. A., Asuncion, A., Bedolla, R. G., Vinall, R. L., Tepper, C. G., Gandour‐Edwards, R. F., Shi, X.-B., et al. (2023) · doi:10.1158/0008-5472.c.6500427
Self-citationMyofibrillar protein accumulation but reduced protein synthesis in PDCD4-depleted myotubes
Mora, S., Alihemmat, L., Davari, L., Ataie, T., Mehranjani, P. N., Flewwelling, L. D., Cheng, A. J., & Adegoke, O. A. J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345305
Signalisation et ciblage thérapeutique du récepteur tyrosine kinase AXL dans les cancers
Leconet, W. (2014) · theses.fr (ABES) · doi:10.70675/e91475a6z3b26z42ecza153zdc13a97fb5ec
Maassarani, M. E. (2014) · theses.fr (ABES) · doi:10.70675/23a6340az9ee7z4fa8z8fd4zc402184ff6e8
Morato, A. (n.d.) · Institutional Research Information System University of Turin (University of Turin)
Metadata
- Authors
- Cao, Z., Wu, X., Yen, L., Sweeney, C., & Carraway, K. L.
- Affiliations
- UC Davis Comprehensive Cancer Center (US)
- Corresponding author
- Carraway, Kermit L.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2007-03-01
- Volume
- 27
- Issue
- 6
- Pages
- 2180-2188
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC1820496
- OpenAlex
- W2149674434
- Cited by
- 119
- References
- 57
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 12 · 2015: 8 · 2014: 12 · 2013: 10 · 2012: 4
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (GM068994, CA118384)
- National Cancer Institute (CA123541, R01CA118384, R01CA123541, CA118384)
- National Institute of General Medical Sciences (R01GM068994, GM068994)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- neuregulin-1, HER3, Nrdp1, USP8, deubiquitinase, protein stability, receptor degradation, E3 ubiquitin ligase, Akt phosphorylation, MCF-7 cells, ubiquitination
- MeSH terms
- Animals, Cell Line, Chlorocebus aethiops, Humans, Endopeptidases, Phosphothreonine, Protein Binding, Signal Transduction, Down-Regulation, Phosphatidylinositol 3-Kinases, Neuregulin-1, Receptor, ErbB-3, Ubiquitin, Ubiquitin Thiolesterase, Ubiquitin-Protein Ligases, Proto-Oncogene Proteins c-akt, Endosomal Sorting Complexes Required for Transport
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.